Avantor, Inc. (AVTR) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights several concerns: projected negative organic revenue growth, expected EBITDA margin contraction, and specific headwinds in the BMP segment. While there is confidence in second-half recovery and some positive order trends, the overall guidance is weak, with significant headwinds and uncertainties, particularly in the VWR and BMP segments. The lack of specific guidance on gross margins and the negative impact of idiosyncratic headwinds further contribute to a negative sentiment. Given these factors, a negative stock price movement is anticipated over the next two weeks.
Key Financial Performance
VWR Distribution and Services Revenue $1.15 billion in Q1 2026, down 5% organically year-over-year. Decline attributed to soft market conditions in Europe, adverse winter weather in the U.S., and volume declines.
BMP Revenue $431 million in Q1 2026, down 2% organically year-over-year. Decline influenced by tough comparisons, normalization of customer ordering patterns, and lower volumes in certain segments like Fluid Handling and NuSil.
Total Revenue $1.581 billion in Q1 2026, down 4% organically and flat year-over-year on a reported basis. Decline due to volume reductions and market dynamics.
Adjusted EBITDA $219 million in Q1 2026 with a margin of 13.9%. Decline attributed to lower volumes, mix, and inventory provisions.
Adjusted EPS $0.17 in Q1 2026, ahead of expectations due to strong execution in BMP, particularly in process chemicals and NuSil.
Free Cash Flow $25 million in Q1 2026 ($39 million excluding restructuring costs). Decline influenced by customer prebates and restructuring costs.
Adjusted Net Leverage Ratio 3.3x adjusted EBITDA at the end of Q1 2026, up 0.1 points year-over-year due to lower trailing 12-month adjusted EBITDA.
VWR Adjusted Operating Income $105 million in Q1 2026 with a margin of 9.2%. Decline due to volume reductions, net price capture, and increased freight costs.
BMP Adjusted Operating Income $103 million in Q1 2026 with a margin of 23.8%. Decline due to inventory provisions, lower volumes, and mix.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Bioscience and Medtech Products (BMP): Revenue was $431 million in Q1, down 2% organically versus the previous year. Improved execution in process chemicals and NuSil contributed to better-than-expected results. Revival efforts are showing modest operational improvements.
VWR e-commerce platform: Showed improved performance in traffic, conversion, and revenue growth following upgrades and the relaunch of vwr.com.
Geographic market performance: Soft market conditions in Europe and adverse winter weather in the U.S. impacted revenue. European market weakness was a notable factor.
Operational improvements: Kaizen events and modular automation projects were implemented to enhance workflows, quality, compliance, and throughput. These efforts are expected to reduce costs and improve operational efficiency.
Leadership changes: Approximately 25% of the senior leadership team was refreshed, including new roles such as Chief Digital Officer and Chief Transformation Officer, to drive Revival efforts.
Revival initiative: Focused on improving execution, accountability, and customer service. Revival is already positively impacting operational and financial performance.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: Soft market conditions in Europe and adverse winter weather in the U.S. negatively impacted revenue, particularly in the VWR Distribution & Services segment.
Economic Uncertainties: Inflationary pressures stemming from the Middle East conflict are creating cost headwinds, estimated at $10 million to $20 million for 2026 operating income.
Supply Chain Pressures: Concerns about the price of raw materials and services due to global inflationary pressures, with potential risks to availability if conflicts persist.
Segment-Specific Challenges: The VWR segment experienced a 5% organic revenue decline due to European market weakness and industry dynamics. BMP segment faced a 2% organic revenue decline, with headwinds from idiosyncratic customer ordering patterns and shipments in 2025.
Operational Risks: Increased freight costs and inventory provisions negatively impacted margins. Operational inefficiencies in certain manufacturing processes required investments in automation to improve quality, compliance, and throughput.
Competitive Pressures: The company is facing tough year-over-year comparisons in BMP, particularly in fluid handling, process chemicals, and NuSil, which are expected to worsen in Q2.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Avantor expects organic revenue growth in the second half of 2026, with VWR's growth rate improving gradually and turning positive in the latter half of the year. BMP's growth rate is expected to reach a low point in Q2 2026 before improving.
Adjusted EPS: The company projects adjusted EPS of $0.19 to $0.20 for Q2 2026.
Inflationary Pressures: Inflationary pressures stemming from the Middle East conflict are estimated to create a $10 million to $20 million headwind to 2026 operating income. A task force has been established to monitor and mitigate these pressures.
Segment Margins: Adjusted operating margins for both VWR and BMP segments are expected to increase sequentially from Q1 to Q2 2026, following seasonal patterns.
Capital Allocation: Debt reduction remains the top priority, with a commitment to reducing the adjusted net leverage ratio sustainably below 3x.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the countermeasures you're taking to offset incremental inflation, particularly in transportation costs?
A:The company has a new Chief Procurement Officer, Keith Burgio, and has established a task force to address inflation in inbound and outbound freight and critical materials. They are evaluating the impact of a $10 million to $20 million headwind and considering passing costs to customers.
Q:What is the significance of the book-to-bill ratio in the BMP segment, and what is the lead time for revenue growth?
A:The book-to-bill ratio in the BMP segment is greater than 1.1, indicating strong order intake. Lead times for products range from 30 to 90 days, depending on customer visibility and blanket orders. The company is confident about returning to growth in the second half of the year.
Q:Can you provide specifics on 2Q organic growth and margins for VWR and BMP?
A:VWR is expected to improve sequentially, while BMP will see lower organic growth due to idiosyncratic comps. Margins are expected to increase modestly due to better fixed cost absorption and cost-out initiatives.
Q:What are you hearing from BMP customers, and what is the visibility into recovery?
A:The biopharma market is healthy, particularly in bioproduction and process chemicals. The academic and government markets are stable but with lower activity. The company is confident in recovery due to strong order books and customer feedback.
Q:Can you provide an organic growth number for 2Q?
A:The company expects a decline of 500 basis points at the enterprise level for 2Q.
Q:What gives you confidence that VWR has bottomed out in Q1?
A:The company has stabilized the situation with VWR, improved order trends, and strengthened the team. They expect stabilization in Q2 and positive growth thereafter.
Q:What improves in the back half of the year to achieve positive growth?
A:Stabilization of VWR, a strong order book for BMP, and the impact of Revival initiatives on commercial intensity and operational excellence contribute to confidence in second-half growth.
Q:What portion of your manufacturing and logistics facilities are in good shape, and what investments are needed?
A:Most facilities are in good shape, with ongoing projects to improve productivity. The company completed 12 projects in Q1 and expects more throughout the year.
Q:How do BMP idiosyncratic order pattern comps evolve throughout the year?
A:Idiosyncratic order patterns will improve in the back half of the year, with sequential stability and modest growth expected.
Q:Can you discuss price versus volume performance in the quarter and updated pricing expectations for the year?
A:Pricing was positive in BMP but negative in VWR due to margin resets. The company expects gross margin improvement throughout the year.
Q:Can you explain the free cash flow performance in Q1 and the guide for the year?
A:Free cash flow was $25 million in Q1, consistent with expectations. The guide of $500 million to $550 million includes a significant step-up in the coming quarters, driven by seasonal improvements and lower restructuring expenses.
Q:What is the impact of weather on VWR in Q1, and how does it affect Q2?
A:Weather impacted Q1, but the team managed to deliver expected results. There is no significant carryover impact into Q2.
Q:What is the inflationary impact of $10 million to $20 million, and can freight-related surcharges be passed through?
A:The company has tools to implement surcharges, which worked well post-COVID. They are monitoring the Middle East conflict for potential additional headwinds.
Q:What is the long-term growth potential for the bioprocess portfolio?
A:The company expects the bioprocess market to grow at 6%-7% and aims to grow at or above market rates, with confidence in second-half growth.
Q:What structural changes have been made since the CEO joined, and what remains to be done?
A:The company has made significant leadership changes, including creating new roles and empowering teams. The CEO expects to complete structural changes within a few months.
Q:What is the impact of prebates on cash flow, and how does it affect future quarters?
A:Prebates significantly impacted Q1 cash flow but were anticipated. They are associated with enterprise contracts and indicate contract renewals and wins.
Q:What is the broader market outlook for the distribution business?
A:The academic and government markets are stable but at low levels. Industrial markets in Europe are struggling. The company expects stabilization and growth in the second half.
Q:What is the impact of idiosyncratic headwinds in BMP, and how do they evolve?
A:NuSil and Serum headwinds impact the first half, while electronic materials impact the second half. Sequential improvement is expected throughout the year.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the portion of plasticware portfolio within VWR that is owned versus OEM, citing a lack of immediate data. Additionally, they did not provide detailed gross margin expectations for the back half of the year, only indicating gradual improvement.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Accounting Officer
Bioscience Medtech
Chief Accounting
East conflict
Head VWR
Middle East
President Investor
VWR platform
VWR rate
automation
bulk
comp headwind
corner VWR
council
customer pattern
eye term
finance
kaizen event
leverage ratio
map relaunch
pattern shipment
platform shoot
process chemical
project
rate bottom
report
road map
shoot traffic
slide
talent
traffic conversion
upgrade
AVTR Transcript
Avantor, Inc. (AVTR) Q1 2026 Earnings Call Transcript
Unknown4-29
The earnings call highlights several concerns: projected negative organic revenue growth, expected EBITDA margin contraction, and specific headwinds in the BMP segment. While there is confidence in second-half recovery and some positive order trends, the overall guidance is weak, with significant headwinds and uncertainties, particularly in the VWR and BMP segments. The lack of specific guidance on gross margins and the negative impact of idiosyncratic headwinds further contribute to a negative sentiment. Given these factors, a negative stock price movement is anticipated over the next two weeks.
Avantor, Inc. (AVTR) Q4 2025 Earnings Call Transcript
Unknown2-11
The earnings call reveals several concerning factors: declining revenue and profitability projections, reduced EPS guidance, and significant operational challenges requiring costly investments. The Q&A section highlights further uncertainties, including unclear guidance on key metrics and growth rates. Additionally, the company's cautious stance on guidance and lack of clarity on investment impacts contribute to a negative outlook. Despite some positive elements like cost-saving initiatives and strategic investments, the overall sentiment is negative due to the prevailing financial and operational headwinds.
Avantor, Inc. (AVTR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Avantor, Inc. (AVTR) Q3 2025 Earnings Call Transcript
Unknown10-29
The earnings call summary reveals lowered revenue growth expectations, reduced EBITDA margins, and a decrease in free cash flow. The Q&A section highlights management's avoidance of concrete answers about future growth and unresolved operational challenges, such as share losses and plant downtime. Although there are strategic investments and a stock buyback plan, the overall sentiment remains negative due to weak guidance and market uncertainties.
AVTR Slides
AVTR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
